Severo Ochoa Programme 2018-2022 News Health News Severo Ochoa Health News - ICN2Tuesday, 14 March 2023
The jury recognised the enormous relevance of the research led by Prof. Lechuga, in particular in developing new diagnostic methods, and her commitment to promoting technology transfer.
Monday, 06 March 2023
A research published in ACS Nano and featured on the cover of the issue proposes externally controlled iron magnetoplasmonic nanocapsules for cancer treatment. Satisfactory results have already been obtained in the preclinical phase in mice. This study was carried out by reseachers from the Barcelona Institute of Microelectronics (IMB-CNM-CSIC), the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the Hebrew University of Jerusalem (HU).
Wednesday, 01 March 2023
ICN2 showcases four of its most promising spin-off companies at the 4YFN (4 Years From Now) event held in Barcelona during MWC23. InBrain Neuroelectronics, Napptilus Battery Labs, Paperdrop Diagnostics, and Cooling Photonics presented their cutting-edge technologies and business models to potential investors and collaborators.
Friday, 24 February 2023
A study published in ACS sensor and led by members of the ICN2 Nanobioelectronics and Biosensors Group introduces a one-step, versatile technique to produce nanocomposite films (made of reduced graphene oxide embedding metal nanoparticles) to be used as sensing substrates for different applications. The simplicity of this approach can allow scaling sensor production and reducing costs.
Thursday, 26 January 2023
Experts in various branches of nanomedicine discuss recent developments and provide their vision about the future of the field in a Roadmap article published in the 'Journal of Physics, Materials'. Researchers from the ICN2 Nanostructured Functional Materials Group and the Universitat Autónoma de Barcelona contributed a section dedicated to the use of nanoparticles as carriers for drug delivery in Parkinson’s disease treatments.
Friday, 23 December 2022
He carried our research on graphene-based devices for cell bioelectronics at the ICN2 in the Advanced Electronics Materials and Device Group. The prize was awarded on December 22.
Tuesday, 20 December 2022
A highly competitive process led to successful recommendation by the European Commission to provide up to 15M€ investment in INBRAIN Neuroelectronics. Funding will be used to support the development of the world’s first graphene intelligent brain network platform towards commercialization.
Monday, 12 December 2022
They developed their thesis project under the supervision of group leader Prof. José Garrido (ICN2) and Dr Anton Guimerà (IMB-CNM-CSIC).
Thursday, 01 December 2022
A team of researchers led by members of the ICN2 NanoBiosensors and Bioanalytical Applications Group presents on the pages of ‘Sensors & Diagnostics’ an innovative photonic biosensor that can detect the presence of the SARS-COV-2 virus at very low concentrations in a sample. It can also provide a quantitative measure of the viral load in less than 20 minutes, which is crucial to prevent the spread of the infection and to intervene quickly with the appropriate treatment.
Wednesday, 16 November 2022
Thanks to this funding, researchers at the ICN2 will develop photo-sensitive materials for smart windows, membranes for skin regeneration and a device for rapid detection and discrimination of respiratory viruses.
Friday, 11 November 2022
The project eNLIGHT, led by Prof. Lechuga, will receive 30,000€ to develop an optical nanodevice that can provide rapid, effective and quantitative diagnosis of lung cancer from a small sample of human blood.
Thursday, 29 September 2022
Former PhD student at the ICN2 in the Nanobioelectronics and Biosensors Group led by Prof. Arben Merkoçi.
Thursday, 22 September 2022
The Barcelona Deep Tech Summit (September 22) unfolds a dense programme of roundtables, discussions, and pitches for investors.
Monday, 05 September 2022
A team consisting of current and former members of the ICN2 Nanobioelectronics and Biosensors Group has developed an electrochemical sensor based on a modified DNA scaffold nanostructure able to detect antibodies and proteins in unprocessed biological fluids. It has a Y-shaped architecture that mimics the one of natural Immunoglobulin antibodies. According to the results published in an article in ‘Advanced Functional Materials’, it is selective, specific, and adaptable to the detection of different biomarkers.
Wednesday, 31 August 2022
The WHO R&D Blueprint organised this consultation with experts in the field to apply scientific lessons learned during the SARS-CoV-2 global pandemic and draw an outline list of scientific gaps and priority research questions to prepare for pathogens with epidemic and pandemic potential.
Thursday, 04 August 2022
Nanophotonic (bio)sensors and some leading researchers working on various applications of this family of technologies are featured in an article in the “Nature Tech” Collection.
Wednesday, 15 June 2022
A new publication dedicated to bioengineering, with a special focus on applications and technology transfer, is being added to the Nature journal portfolio. In a seminar held at the ICN2, Chief Editor Dr Horejs presented the journal and discussed key aspects of the review and publication process in Nature-Springer.
Tuesday, 14 June 2022
The actuality and prolific nature of the topic called for a second special issue. ICN2 group leaders Prof. Merkoçi and Prof. Lechuga signed the editorial.
Wednesday, 08 June 2022
In this lecture, ICN2 Director Prof. Pablo Ordejón explained the role of nanotechnology in addressing major challenges in health, energy, environment, and other fields and provided examples of existing applications and new developments.
Monday, 30 May 2022
The event, which was organised by group leader Prof. Laura Lechuga and counted on the participations of many members of the ICN2 community, aimed at bringing together researchers in the field on nanomedicine, clinicians from relevant hospitals, and healthcare industry experts to share results and views both on recent advances in the field and on effective procedures to transfer new technologies into clinical practice.
